Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
Aged
Aged, 80 and over
Aging
/ physiology
Breast Neoplasms
/ epidemiology
Cohort Studies
Colorectal Neoplasms
/ epidemiology
Diabetes Mellitus
/ epidemiology
Europe
/ epidemiology
Female
Humans
Male
Middle Aged
Neoplasms
/ epidemiology
Prevalence
Prostatic Neoplasms
/ epidemiology
Risk Factors
United States
/ epidemiology
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
27
07
2020
accepted:
04
03
2021
revised:
28
02
2021
pubmed:
28
3
2021
medline:
16
12
2021
entrez:
27
3
2021
Statut:
ppublish
Résumé
We investigated whether associations between prevalent diabetes and cancer risk are pertinent to older adults and whether associations differ across subgroups of age, body weight status or levels of physical activity. We harmonised data from seven prospective cohort studies of older individuals in Europe and the United States participating in the CHANCES consortium. Cox proportional hazard regression was used to estimate the associations of prevalent diabetes with cancer risk (all cancers combined, and for colorectum, prostate and breast). We calculated summary risk estimates across cohorts using pooled analysis and random-effects meta-analysis. A total of 667,916 individuals were included with an overall median (P25-P75) age at recruitment of 62.3 (57-67) years. During a median follow-up time of 10.5 years, 114,404 total cancer cases were ascertained. Diabetes was not associated with the risk of all cancers combined (hazard ratio (HR) = 0.94; 95% confidence interval (CI): 0.86-1.04; I Prevalent diabetes was positively associated with colorectal cancer risk and inversely associated with prostate cancer risk in older Europeans and Americans.
Sections du résumé
BACKGROUND
We investigated whether associations between prevalent diabetes and cancer risk are pertinent to older adults and whether associations differ across subgroups of age, body weight status or levels of physical activity.
METHODS
We harmonised data from seven prospective cohort studies of older individuals in Europe and the United States participating in the CHANCES consortium. Cox proportional hazard regression was used to estimate the associations of prevalent diabetes with cancer risk (all cancers combined, and for colorectum, prostate and breast). We calculated summary risk estimates across cohorts using pooled analysis and random-effects meta-analysis.
RESULTS
A total of 667,916 individuals were included with an overall median (P25-P75) age at recruitment of 62.3 (57-67) years. During a median follow-up time of 10.5 years, 114,404 total cancer cases were ascertained. Diabetes was not associated with the risk of all cancers combined (hazard ratio (HR) = 0.94; 95% confidence interval (CI): 0.86-1.04; I
CONCLUSIONS
Prevalent diabetes was positively associated with colorectal cancer risk and inversely associated with prostate cancer risk in older Europeans and Americans.
Identifiants
pubmed: 33772152
doi: 10.1038/s41416-021-01347-4
pii: 10.1038/s41416-021-01347-4
pmc: PMC8144608
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1882-1890Subventions
Organisme : Medical Research Council
ID : G0601463
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K023241/1
Pays : United Kingdom
Références
Chatterjee, S., Khunti, K. & Davies, M. J. Type 2 diabetes. Lancet 389, 2239–2251 (2017).
pubmed: 28190580
doi: 10.1016/S0140-6736(17)30058-2
Zheng, Y., Ley, S. H. & Hu, F. B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 14, 88–98 (2018).
pubmed: 29219149
doi: 10.1038/nrendo.2017.151
Ohkuma, T., Peters, S. A. E. & Woodward, M. Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events. Diabetologia 61, 2140–2154 (2018).
pubmed: 30027404
pmcid: 6133170
doi: 10.1007/s00125-018-4664-5
Gouveri, E., Papanas, N. & Maltezos, E. The female breast and diabetes. Breast 20, 205–211 (2011).
pubmed: 21414785
doi: 10.1016/j.breast.2011.02.019
Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E. & Ioannidis, J. P. A. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350, g7607 (2015).
pubmed: 25555821
doi: 10.1136/bmj.g7607
Bansal, D., Bhansali, A., Kapil, G., Undela, K. & Tiwari, P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 16, 151–158 (2013). S1.
pubmed: 23032360
doi: 10.1038/pcan.2012.40
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clinicians. 68, 394–424 (2018).
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A. et al. Diabetes and cancer: a consensus report. CA Cancer J. Clin. 60, 207–221 (2010).
pubmed: 20554718
doi: 10.3322/caac.20078
Lynch, B. M., Neilson, H. K. & Friedenreich, C. M. Physical activity and breast cancer prevention. Recent Results Cancer Res. 186, 13–42 (2011).
pubmed: 21113759
doi: 10.1007/978-3-642-04231-7_2
Steindorf, K., Ritte, R., Eomois, P.-P., Lukanova, A., Tjonneland, A., Johnsen, N. F. et al. Physical activity and risk of breast cancer overall and by hormone receptor status: the European prospective investigation into cancer and nutrition. Int. J. Cancer 132, 1667–1678 (2013).
pubmed: 22903273
doi: 10.1002/ijc.27778
Amadou, A., Hainaut, P. & Romieu, I. Role of obesity in the risk of breast cancer: lessons from anthropometry. J. Oncol. 2013, 906495 (2013).
pubmed: 23431300
pmcid: 3575614
doi: 10.1155/2013/906495
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F. & Zwahlen, M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–578 (2008).
pubmed: 18280327
doi: 10.1016/S0140-6736(08)60269-X
Zhang, P., Li, H., Tan, X., Chen, L. & Wang, S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 37, 207–218 (2013).
pubmed: 23352629
doi: 10.1016/j.canep.2012.12.009
Boffetta, P., Bobak, M., Borsch-Supan, A., Brenner, H., Eriksson, S., Grodstein, F. et al. The Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES) project–design, population and data harmonization of a large-scale, international study. Eur. J. Epidemiol. 29, 929–936 (2014).
pubmed: 25504016
doi: 10.1007/s10654-014-9977-1
Lai, G. Y., Park, Y., Hartge, P., Hollenbeck, A. R. & Freedman, N. D. The association between self-reported diabetes and cancer incidence in the. J. Clin. Endocrinol. Metab. 98, E497–E502 (2013).
pubmed: 23408570
pmcid: 3590471
doi: 10.1210/jc.2012-3335
Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy [Internet]. (WHO Guidelines Approved by the Guidelines Review Committee). http://www.ncbi.nlm.nih.gov/books/NBK169024/ (WHO, 2013).
FIN-EAS and FIN-WES: FINRISK Study [Internet]. https://www.thl.fi/publications/morgam/cohorts/full/finland/fin-fina.htm#dprocedure (2020).
Tsilidis, K. K., Papadimitriou, N., Capothanassi, D., Bamia, C., Benetou, V., Jenab, M. et al. Burden of Cancer In A Large Consortium Of Prospective Cohorts in Europe. J. Natl Cancer Inst. 108, https://academic.oup.com/jnci/article/108/10/djw127/2412485 (2016).
DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 7, 177–188 (1986).
pubmed: 3802833
doi: 10.1016/0197-2456(86)90046-2
Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002).
pubmed: 12111919
doi: 10.1002/sim.1186
Dankner, R., Boffetta, P., Balicer, R. D., Boker, L. K., Sadeh, M., Berlin, A. et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am. J. Epidemiol. 183, 1098–1106 (2016).
pubmed: 27257115
doi: 10.1093/aje/kwv290
Peila, R. & Rohan, T. E. Diabetes, glycated hemoglobin, and risk of cancer in the UK biobank study. Cancer Epidemiol. Biomark. Prev. 29, 1107–1119 (2020).
doi: 10.1158/1055-9965.EPI-19-1623
Ling, S., Brown, K., Miksza, J. K., Howells, L., Morrison, A., Issa, E. et al. Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. Diabetes Care. 43, 2313–2322 (2020).
pubmed: 32910779
doi: 10.2337/dc20-0204
Xu, H., Jiang, H., Ding, G., Zhang, H., Zhang, L., Mao, S. et al. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 99, 241–249 (2013).
pubmed: 23298664
doi: 10.1016/j.diabres.2012.12.003
Jayedi, A., Djafarian, K., Rezagholizadeh, F., Mirzababaei, A., Hajimohammadi, M. & Shab-Bidar, S. Fasting blood glucose and risk of prostate cancer: a systematic review and meta-analysis of dose-response. Diabetes Metab. 44, 320–327 (2018).
pubmed: 29074328
doi: 10.1016/j.diabet.2017.09.004
Au Yeung, S. L. & Schooling, C. M. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study. BMJ Open Diabetes Res. Care 7, e000872 (2019).
pubmed: 31908803
pmcid: 6936416
doi: 10.1136/bmjdrc-2019-000872
Dankner, R., Boffetta, P., Keinan-Boker, L., Balicer, R. D., Berlin, A., Olmer, L. et al. Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men. Diabetologia 59, 1683–1691 (2016).
pubmed: 27189066
pmcid: 4930460
doi: 10.1007/s00125-016-3972-x
Larsson, S. C., Mantzoros, C. S. & Wolk, A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer 121, 856–862 (2007).
pubmed: 17397032
doi: 10.1002/ijc.22717
Aune, D., Norat, T., Leitzmann, M., Tonstad, S. & Vatten, L. J. Physical activity and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis. Eur. J. Epidemiol. 30, 529–542 (2015).
pubmed: 26092138
doi: 10.1007/s10654-015-0056-z
Lee, J., Meyerhardt, J. A., Giovannucci, E. & Jeon, J. Y. Association between body mass index and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies. PLoS ONE 10, e0120706 (2015).
pubmed: 25811460
pmcid: 4374868
doi: 10.1371/journal.pone.0120706
Freisling, H., Arnold, M., Soerjomataram, I., O’Doherty, M. G., Ordonez-Mena, J. M., Bamia, C. et al. Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe. Br. J. Cancer 116, 1486–1497 (2017).
pubmed: 28441380
pmcid: 5520086
doi: 10.1038/bjc.2017.106
PJHL, Peeters, Bazelier, M. T., Leufkens, H. G. M., de Vries, F. & De Bruin, M. L. The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. Diabetes Care 38, 495–502 (2015).
doi: 10.2337/dc14-1175
Moe, B. & Nilsen, T. I. L. Cancer risk in people with diabetes: Does physical activity and adiposity modify the association? Prospective data from the HUNT Study, Norway. J. Diabetes Complicat. 29, 176–179 (2015).
doi: 10.1016/j.jdiacomp.2014.12.001
Fall, K., Garmo, H., Gudbjornsdottir, S., Stattin, P. & Zethelius, B. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol. Biomark. Prev. 22, 1102–1109 (2013).
doi: 10.1158/1055-9965.EPI-12-1046
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G. & Vigneri, R. Diabetes and cancer. Endocr. Relat. Cancer 16, 1103–1123 (2009).
pubmed: 19620249
doi: 10.1677/ERC-09-0087
Novosyadlyy, R., Lann, D. E., Vijayakumar, A., Rowzee, A., Lazzarino, D. A., Fierz, Y. et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 70, 741–751 (2010).
pubmed: 20068149
pmcid: 2946167
doi: 10.1158/0008-5472.CAN-09-2141
Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 21, 297–308 (2012).
pubmed: 22439925
pmcid: 3311998
doi: 10.1016/j.ccr.2012.02.014
Ryu, T. Y., Park, J. & Scherer, P. E. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab. J. 38, 330–336 (2014).
pubmed: 25349819
pmcid: 4209346
doi: 10.4093/dmj.2014.38.5.330
Xu, C.-X., Zhu, H.-H. & Zhu, Y.-M. Diabetes and cancer: associations, mechanisms, and implications for medical practice. World J. Diabetes 5, 372–380 (2014).
pubmed: 24936258
pmcid: 4058741
doi: 10.4239/wjd.v5.i3.372
Rastmanesh, R., Hejazi, J., Marotta, F. & Hara, N. Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms. Clin. Genitourin. Cancer 12, 143–148 (2014).
pubmed: 24513117
doi: 10.1016/j.clgc.2014.01.001
Lau, B., Cole, S. R. & Gange, S. J. Competing risk regression models for epidemiologic data. Am. J. Epidemiol. 170, 244–256 (2009).
pubmed: 19494242
pmcid: 2732996
doi: 10.1093/aje/kwp107
Kowall, B., Stang, A., Rathmann, W. & Kostev, K. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol. Drug Saf. 24, 865–874 (2015).
pubmed: 26132313
doi: 10.1002/pds.3823
Feng, Z., Zhou, X., Liu, N., Wang, J., Chen, X. & Xu, X. Metformin use and prostate cancer risk: a meta-analysis of cohort studies. Medicine 98, e14955 (2019).
pubmed: 30896668
pmcid: 6709307
doi: 10.1097/MD.0000000000014955
Qiu, S., Cai, X., Wu, T., Sun, Z., Guo, H., Kirsten, J. et al. Objectively-measured light-intensity physical activity and risk of cancer mortality: a meta-analysis of prospective cohort studies. Cancer Epidemiol. Biomark. Prev. 29, 1067–1073 (2020).
doi: 10.1158/1055-9965.EPI-19-1446
Dallal, C. M., Brinton, L. A., Matthews, C. E., Lissowska, J., Peplonska, B., Hartman, T. J. et al. Accelerometer-based measures of active and sedentary behavior in relation to breast cancer risk. Breast Cancer Res. Treat. 134, 1279–1290 (2012).
pubmed: 22752209
pmcid: 3534981
doi: 10.1007/s10549-012-2129-y
Dohrn, I.-M., Welmer, A.-K. & Hagströmer, M. Accelerometry-assessed physical activity and sedentary time and associations with chronic disease and hospital visits—a prospective cohort study with 15 years follow-up. Int. J. Behav. Nutr. Phys. Act. 16, 125 (2019).
pubmed: 31818303
pmcid: 6902520
doi: 10.1186/s12966-019-0878-2